Once-Weekly 1.6mg/m2 Bortezomib BCD Regimen in Newly Diagnosed Multiple Myeloma: Better Response and Lower Incidence of Peripheral Neuropathy

In the present study, the effect and toxicity of 1.6mg/m2 and 1.3mg/m2 bortezomib BCD on multiple myeloma (MM) were analyzed retrospectively. From January 2016 to December 2018, 82 newly diagnosed MM patients received minimal 4 cycles of either 1.6mg/m2 (bortezomib 1.6mg/m2, d1, d8, d15, d22; cyclophosphamide 300 mg/m2 d1, d8, d15; dexamethasone 20 mg d1, d2, d8, d9, d15, d16, d22, d23; 35 days per cycle) or 1.3mg/m2 (bortezomib 1.3mg/m2, d1, d4, d8, d11; cyclophosphamide 300 mg/m2 d1, d8, d15; dexamethasone 20 mg d1, d2, d4, d5, d8, d9, d11, d12; 21 days per cycle) bortezomib BCD regimen.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Fangfang Li, Hao Li, Yubin Li, Zhumei Zhan, Wangshan Song, Fanglin Li, Xiangxin Li, Lingling Wang, Yan Wang, Luqun Wang Source Type: research